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Abstract  
The dominant narrative around dementia argues that progression cannot be halted or 
reversed. However, evidence on multimodal non-pharmacological treatments formulated 
around a ‘personalised medicine’ approach challenges this view. This paper reviews the 
current evidence for dementia prevention utilising such treatments and explains the logic of 
applying personalised medicine. The functional medicine treatment approach to ‘root cause’ 
analysis is presented as currently practiced with patients experiencing cognitive decline. We 
report six case reports including in-depth practitioner evaluations, recommendations and 
follow-ups. We cover the various presentations of memory and concentration problems and 
the screening process with advanced functional testing. The case reports appear in a table, 
followed by 11 key points, insights and findings. To our knowledge, this is the first paper 
reporting practitioner case reports documenting improvements in symptoms of memory 
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decline in patients from the UK, Greece and New Zealand. Four patients had initial 
presentations and follow-up improvements verified by standardised screening instruments 
and/or formal diagnosis. Two patients had symptom improvements verified through self-
report and proxy-report. Practitioners reported improvements through biomarkers 
(normalisation of serum levels, folate and homocysteine, thyroid function, blood sugar 
levels), as well as weight loss, decreased blood pressure and reduction in medications. They 
also reported improved mental, physical, social, energetic, emotional and spiritual 
functioning. The next phase is an enhanced intervention alongside the existing UK National 
Health Service memory assessment pathway. This paper advocates for personalised 
medicine in the UK for persons living with memory problems and dementia, driven by this 
increasing evidence base.  
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1. Introduction 
As many as one in three people born in 2015 in the UK will develop dementia in their lifetime 
[1], yet modifiable risk factors contribute to one-third of Alzheimer’s cases [2, 3]. The dominant 
narrative around dementia argues that progression cannot be halted or reversed. Current 
treatment approaches, whether pharmacological or neuropsychological at best delay decline [4]. 
Explosive headlines such as dementia being a ’ticking time-bomb’ and estimates of prevalence 
based on no change in treatment reinforce this account. However, evidence on multimodal non-
pharmacological treatments (MM NPTs) formulated around a ‘personalised medicine’ approach 
challenges this view.  
This paper introduces a novel approach to dementia treatment in the following sections:  
 Dementia prevention - Current evidence on multimodal non-pharmacological treatments 
 The logic of applying personalised medicine to dementia 
 A Functional Medicine (FM) treatment approach – 6 Case Reports 
 Discussion and Conclusion  
To our knowledge, this paper contains the first case reports showing improved 
symptomatology of memory-impaired patients in the UK [3], as well as two in Greece and one in 
New Zealand. It also reports in some depth the approach to root cause analysis, including 
presentations, indications, evaluations, treatment recommendations, outcomes and follow-ups 
over time. The reports give variable depth and extent of patient information as determined by 
each practitioner. Research ethics approval was granted by the Faculty of Health and Medicine 
Research Ethics Committee [FHMREC17047]. 
2. Dementia Prevention – Current Evidence on Multimodal Non-Pharmacological Treatments 
Rather than having a precise neurobiological cause, Alzheimer’s and other dementias represent 
a heterogeneous state, determined by multiple factors and mechanisms that interact and 
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intervene throughout life [5, 6]. Reduction of modifiable risks is currently the preferred strategy to 
reduce future cognitive decline. Modifiable risks include depression, sleep disturbances, smoking, 
obesity, hyperlipidemia, diabetes and hypertension. Remedial actions include further education, 
social engagement, cognitive training, Mediterranean diet, exercise and physical activity [7, 8]. 
Primary prevention trials aim to reduce future prevalence by modifying such factors in healthy or 
at-risk populations [7]. In at-risk elderly people, interventions modifying more than one factor 
have improved or maintained cognitive functioning [9] and seem feasible, cost-effective and 
engaging [10].  
Increasingly, studies investigate secondary or tertiary prevention and seek to interrupt 
cognitive decline or dementia that is already underway [11]. Once a person experiences 
measurable cognitive impairment and receives a diagnosis, treatment interventions could 
potentially be more effective, because the person retains insight. Such studies are promising, tend 
to show a benefit with the intervention group compared to the controls and tend towards higher 
reporting quality [12]. An example is the Body, Brain, Life for Cognitive Decline (BBL-CD) RCT 
providing a multidomain lifestyle intervention to people with subjective cognitive decline (SCD) 
and mild cognitive impairment (MCI) in Australian primary care [13]. The intervention included on-
line education and personal sessions on exercise, diet, nutrition, cognitive engagement, brain 
training and physical activity. All the studies above utilised examples of therapies that are not 
pharmacological. 
Non-pharmacological therapies (NPTs) are a ‘useful, versatile and potentially cost-effective 
approach to improve outcomes and QoL’ in Alzheimer’s disease (AD) and related disorders for 
both the person with dementia and caregivers [14]. Single-domain interventions (nutritional 
supplements, cognitive training and physical activity) for individuals with positive biomarkers and 
cognitive impairment have been shown to be protective of cognitive decline [15].  Physical activity 
also appears to benefit various aspects of cognition including stabilization of MMSE scores, 
improved attention, memory and recognition [16, 17], the ability to perform ADLs and overall 
well-being [18]. For people with cognitive decline or early dementia, NPTs have successfully 
addressed sleep, yoga, exercise and nutrition [19-22] among other domains. Cognitive decline can 
be attenuated by factors such as improved nutrition, appropriate dietary supplementation, 
increased physical exercise, mental exercise and social activities [23].  
Evidence from multimodal studies elucidates possible synergistic effects. Exercise, in 
combination with dietary factors has been demonstrated to affect molecular events related to the 
management of energy metabolism and synaptic plasticity [24]. Randomised controlled trials 
(RCTs) of multimodal interventions find that community-dwelling cognitively impaired elders 
benefit from combining physical, cognitive and social activities [25]. Evidence suggests that 
multiple therapeutic approaches (nutritional, botanical and stimulatory) targeting several 
dysfunctions at once may offer the most benefit with fewer adverse consequences than 
conventional medications [4]. In a 12-week intervention for people with MCI involving diet, 
omega-3 supplements, physical activity, cognitive stimulation, neurofeedback and meditation, 84% 
significantly improved cognitive function and 53% showed hippocampal growth [26]. The 
multimodal approach may thus be effective for improving cognitive function [27] and for 
maintaining or improving cognitive health [28], for persons with mild cognitive impairment (MCI) 
or dementia [29]. However, randomly assigned interventions to treat memory complaints with a 
multidomain intervention and polyunsaturated fatty acids, either alone or in combination, 
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revealed no significant effects on cognitive decline over 3 years [30], which may support 
arguments for a personalised approach.  
A recent systematic review on multimodal non-pharmacological interventions to improve 
cognition for people with dementia [31] noted that group studies used 2-3 modes of intervention 
and multiple methods to implement them. Interventions utilised included cognitive, physical, 
psychological and psychosocial, nutrition, fasting, gut health, sleep hygiene, stress reduction, 
detoxification, hormonal health and oxygen therapy. In 19 (90%) of the 21 group comparisons, 
participants were reported to have cognitive improvements, stability with their dementia or a 
delay in their decline. However, persons treated individually in the five case studies achieved the 
most clinically effective results. Each personalised patient treatment utilised in-depth assessments 
and prescribed up to nine different modes. In cases where cognitive outcomes were improved, 
studies leveraged recent advances in our understanding of the underlying causes of dementia and 
ways to disrupt these neurodegenerative mechanisms. Furthermore, personalised one-to-one 
interactions specific to each individual involving investigation and assessment by the clinician, 
helped to focus or fine-tune the intervention. 
3. The Logic of Applying Personalised Medicine to Cognitive Decline and Dementia   
Personalised medicine addresses chronic disease with a holistic lifestyle approach common to 
Eastern mind-body-spirit traditions, which emphasise prevention rather than treatment, and focus 
on the person instead of the disease [32]. Lifestyle recommendations include healthy eating, 
active living, healthy weight and emotional resilience. A sub-optimal lifestyle is associated with the 
development and prognosis of long-term conditions. An individual’s health metrics (laboratory 
tests, functional biomarkers and other diagnostics) are used to design patient-specific 
prescriptions for diet, exercise, stress and environment. In this way, lifestyle medicine-oriented 
therapeutic strategies can improve individual health outcomes and manage chronic disease [33-
35].  
Underlying this approach is the bodily process of homeostasis whereby the body self-regulates 
to changes within or outside the system to maintain a dynamic state of equilibrium called health 
[36], also formulated as ‘the ability to adapt and self manage’ [37]. Normal mental function 
depends on a balance between synaptoblastic (synapse-making) and synaptoclastic (synapse-
destroying) activity [38]. When maintenance is unbalanced by deficiencies or pollutants, cells 
cannot be replaced and synaptoclastic processes win, resulting in cognitive decline. By correcting 
the environment to support healthy growth and repair while reducing toxins and infections, cells 
can rejuvenate.  
To illustrate this point, consider current findings concerning amyloid-beta protein (Aβ), the 
primary pathological biomarker of Alzheimer’s disease. Why it accumulates is of growing interest. 
Studies suggest β-amyloid deposition is an early innate immune response to infections acting as an 
antimicrobial peptide [39]. This antimicrobial role suggests inflammation propagates AD 
neurodegeneration, and immune pathways mediate pathogen entrapment and protect against 
infection [40]. Amyloid protein may also be evidence of an innate response to destroy fungal 
colonization [41]. Furthermore, we have yet to solve the ‘Amyloid Paradox’, whereby senile 
plaques composed of Aβ contain substantially elevated levels of iron, copper and zinc which bind 
to the Aβ making it toxic to neurons. On the other hand, Aβ can reduce the neurotoxicity of metal 
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ions, suggesting that the interaction can under some circumstances be protective. In studies 
where iron or copper were combined with Aβ, the neurotoxicity of these metals was substantially 
reduced, assisting the antioxidant defense of the brain [42]. Efforts to support plaque removal 
need to be guided by a better understanding of its protective role, and the imbalance of Aβ 
production versus destruction [43]. This gives one more reason to promote neurogenesis by 
supporting the body’s natural equilibrium. 
A personalised and programmatic therapeutic approach called Metabolic Enhancement for 
Neurodegeneration (MEND) has demonstrated the reversal of cognitive decline in patients with 
early AD [44]. This comprehensive precision medicine approach used clinical information and 
metabolic profiling of AD individuals, and provided additional objective evidence that this 
programmatic approach to cognitive decline is highly effective and may enhance pharmaceutical 
efficacy [45]. In some patients, modifications to daily activities, diet, exercise, stress, sleep, etc. 
can mitigate dementia symptoms such that a clinical diagnosis of dementia is no longer justified 
[46]. From the perspective of patient and caregivers, this alone may greatly improve quality of life 
and wellbeing. Over 100 case studies have now reported improvement in cognition, with some 
cases presenting electrophysiology or imaging of morphological structure as well as recovery of 
functional neurocognitive status [47, 48].  
Personalised multimodal medicine (aka holistic [49], natural [32] or FM [50] as a ‘whole systems’ 
approach [51] is therefore logically suited to address cognitive decline or dementia because it 
identifies individual causative factors through in-depth investigation and root cause analysis. The 
practitioner asks not “What?” but “Why?” and prescribes an intervention as a ‘disease modifying 
therapy’ (DMT) that targets change in the underlying disease process leading to cell death [52]. 
The mechanisms and determinants are many [53] and predominantly involve nutritional deficiency 
[54], inflammation [55], oxidative stress [56], mitochondrial dysfunction [57], impaired 
methylation pathways [58], impaired Aβ clearance [43], hormone imbalance [59], chronic stress 
[60], gut dysbiosis [61], insulin dysregulation [62], infections [40, 63-66], poor sleep [67], vascular 
disease [68], and toxicity [41, 60, 69, 70], including heavy metals [71-75].  
Recommendations to address these include diet and nutrition [22, 76] with an emphasis on 
healthy diets such as the Mediterranean, DASH, MIND and plant-based diets, whole foods, 
vegetables and fruits, probiotics, antioxidants, nuts and seeds and Omega-3 fatty acids [77-79] and 
nutritional support [80-82]. Recent findings support a low carbohydrate, high fat diet in which 
saturated fats (olive oil, butter, coconut oil) are advised over manufactured fats and seed oils [83-
85]. The ketogenic diet [86, 87] and medium-chain triglycerides (MCTs) are also recommended 
[87]. Further recommendations include exercise [88-90], stress reduction, fasting [91, 92], 
cognitive stimulation and sleep hygiene [67].  
Having first summarised the current evidence on MM NPTs we then explained the logic of 
applying personalised medicine to dementia. In what follows, we draw on 6 patient case reports to 
demonstrate how practitioners are operationalising this personalised FM approach to the 
treatment of their patients with cognitive decline, Alzheimer’s and other dementias. To clarify, 
cognitive decline or cognitive impairment are terms used to describe symptoms that may or may 
not precede dementia. The evidence is inconclusive as to any correlation between such symptoms 
and dementia, as the standards of proof can never be ethically met [93]. However, in the following 
case reports, patients presented with some form of cognitive impairment, decline or memory 
issues, most of which had progressed to a dementia.  
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These case reports are novel in showing marked improvement in symptoms for what is 
currently by conventional medicine considered an irreversible condition. These reports are not 
case studies, ie, not research exercises with a specified treatment period, treatment protocol and 
target outcomes. They provide instead a brief description of the patient’s clinical and demographic 
details, the diagnosis, any interventions and the outcomes as specified in the BMC Medical 
Research methodology [94] and the CARE [95] guidelines. Importantly, these findings shed new 
light on the possible pathogenesis of the disease which may, based on publication of these and 
similar early patient reports [47, 48], prove to be ultimately treatable with this novel ‘root cause’ 
analysis approach. 
4. Functional Medicine (FM) Treatment Approach - 6 Case Reports  
As with other personalised medicine (holistic, integrative or natural) treating the person is 
paramount to treating a particular problem. FM [96] is a systems biology–based approach that 
focuses on identifying and addressing the root causes of disease.  
Practitioners use low-risk interventions that modify molecular and cellular systems to reverse 
the drivers of disease. The FM approach is particularly useful for treating a disorder like cognitive 
impairment, where one condition can be driven by many causes. Cognitive impairment is driven by 
inflammation, insulin resistance, gut dysbiosis, metabolic syndrome, nutrient deficiencies, toxicity, 
infections, and so on (Figure 1). The underlying causes are also interlinked and respond to similar 
mechanisms. So treating one of the causes may synergistically alter and improve another. 
www.ifm.org   
 
Figure 1 Identified drivers of cognitive impairment. 




Those with memory and concentration problems tend to belong to one of several categories of 
presentation: 
 Many have chronic fatigue symptoms with both physical and mental fatigue (often described 
as ‘brain fog’). As the brain consumes around 22% of the energy created by the body per day, 
anything leading to lack of energy production will inevitably impact on cognitive processing. 
This can be associated with unusual neurological symptoms such as blurred vision, tinnitus 
and pain syndromes / fibromyalgia. 
 Some patients have cognitive dysfunction linked to toxicity - often due to genetic or 
acquired chemical processing issues. These can lead to severe side effects where other 
individuals with similar exposure may suffer no effects. Many of these patients have 
accompanying chemical sensitivities and are unable to tolerate volatile organics or even 
perfumes. Examples include those with ammonia overload (from trans-sulphuration 
pathway defects and bacterial overgrowth), and patients with exposures to heavy metals 
accompanied by poor metals elimination processing. 
 Some have endocrine dysfunction which has not been recognised or adequately treated. 
Hypothyroidism is a common presentation – when untreated this leads to fatigue, low mood, 
poor concentration and metabolic syndrome. 
 Some have specific nutritional deficits leading to poor metabolism and malfunctioning 
mitochondria, poor methylation capacity or neurological damage. Unrecognised B12 
deficiency, folate deficiency and metabolic problems with folate and B12 are common 
causes of neuro-cognitive malfunction. This can lead to peripheral neuropathy, pain 
syndromes, low mood, poor concentration, insomnia and memory losses. Due to the 
difficulty of identifying B12 metabolism disorders in some patients, a course of B12 
injections will be routinely trialled with any patient with neurocognitive dysfunction, fatigue 
or peripheral neuropathy. However, where possible they will be screened for serum B12, 
methylmalonic acid and homocysteine levels first. 
 Other miscellaneous syndromes presenting with subjective cognitive dysfunction include 
those with intractable insomnia, severe mood disorders and specific drugs (opiates, anti-
epileptics / nerve pain-killers). 
Many of these categories will overlap (patients often have low B12, Vitamin D deficiency and 
Hypothyroidism for example). This indicates the importance of looking for all underlying 
contributing factors and addressing them to give the patient the best chance of recovery. 
4.2 Screening 
FM practitioners proceed with a detailed intake process and dietary analysis (captured in a 
lengthy, in-depth questionnaire). In addition to routine haematology, biochemistry, hormone 
levels, HbA1c and thyroid screen, some advanced functional testing is arranged to establish the 
potential contributors to cognitive decline. Patients with neuro-cognitive problems and/or fatigue 
are generally screened for: 
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 Hypothyroidism and T4 to T3 conversion disorder (T4 and T3 are hormones containing 
iodine, that are produced by the thyroid gland. The thyroid produces mainly T4, which is 
then converted to T3, in tissue and organs. T3 is the active hormone.) 
 B12 and folate deficiencies / metabolism disorders 
 All other B vitamin deficiencies 
 Vitamin D deficiency 
 Iron deficiency / overload / anaemia 
 High ammonia / nitrogen overload 
 Miscellaneous metabolic disorders (with organic acids) 
 Possible contributing medications / supplements 
 Risk factors for toxicity / heavy metals exposure (all screened for dental amalgam) / mold 
 GI map genetic stool test and Small Intestine Bacterial Overgrowth (SIBO) breath test 
 Home "burp" test to assess adequacy of stomach acid 
 DUTCH (urine and saliva based) adrenal and hormone testing  
 Yeast and bacterial overgrowth (organic acid testing)  
 Chronic viral screen; Oral and nasal swabs; Candida questionnaire; Allergies 
 Trauma 
They may also consider testing salivary cortisol levels and ordering a hair analysis for heavy 
metals. Blood tests determine the need for vitamin support, blood glucose support and thyroid 
support. (Patients on warfarin are not given Vitamin D with K2.) A homocysteine blood test is used 
for B vitamin support with folate, B12 and B6. Adrenal support (fatigue, anxiety) and sleep support 
supplements depend on the questionnaire. After the first 8 weeks neurotrophic support can be 
added with Bacopa monnieri and Lion’s mane mushroom. Detox support depends on the hair 
analysis. One must wait 2-3 months before detoxing. 
Upon receiving test results the practitioner analyses these data to determine what processes 
are compromised by what mechanism or input. The aim is to identify the root causes of the 
disturbance and adjust the process through lifestyle and supplements, in order for the body to 
regain homeostasis.  
4.3 Case Reports 
Six case reports are given from four medical practitioners involving patients with cognitive 
decline and/or a formal diagnosis of a dementia. All patients gave informed consent to the 
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Table 1 Case reports of patients with cognitive decline or a dementia treated with FM. 
Pt Sex / 
Age 
Presentation Indications / 





•Cognitive decline for 
7-8 yrs. 
•AD confirmed 5 years 
ago 
•Very frail physical 
health - needs help 
with all ADLs 
•Significantly impaired 
cognitive function - day 
to day living fully 
dependent on son with 
whom he lives  




•Vitamin B6 levels were above 
normal at 49.2 (LR 5.0-30.0) 
•Homocysteine elevated - 18.1 
(optimal <7)  
•Vitamin D levels above range 
(at >70 which is high) 
•Interleukin 6 very elevated at 10.99 
(normal <4.0)  
•Ferritin level (120.4) in upper limit 
of normal range (13-150)                                                                                                                                                                            
Thyroid function  
•TSH slightly elevated at 4.320  
•T3 low at 2.24 (normal 3.98 - 6.54)  
•Zinc low at 44 (normal 70-150) 
•Copper higher end of normal at 124 
(65-165) indicates high copper-zinc 
ratio. These showed a moderate 
amount of toxicity but not excessive. 
Interestingly it did show considerably 
higher levels of thorium than I have 
seen in any other person – the 
patient had worked in the nuclear 
industry overseas for many years.  
•Diet (Ketogenic, low carb, hi 
fat) 
•Exercise (don’t sit all day; 
HIIT - high intensity interval 
training)  
•Stress management (Cardio 
Coherence, Buddy App) 
•Address sleep quality 
Supplements 
•Multivitamin/mineral                  
•R-Omega  
•Phyte Inflam  
•Vitamin B12 (methyl and 
adenosyl) sublingual  
•Methyl Factors  
•Probiotic fos-a-dophilus  
•Whole food Zinc                 
•Thyroid Support 
Feedback at 6 months 
• The more closely I follow the advice 
in the Bredesen [97] book the more 
success I have with my father •He is 
mostly bedridden, incredibly weak - he 
cannot stand •My father’s brain 
continues to get better very slowly                               
•Yesterday he asked me about 
something that had occurred 8 hours 
earlier. He has begun to thank me for 
looking after him.                                                            
•I am now including five of Bredesen’s 
[97] Indian herb supplements, as well 
as the ones you recommended. I think 
they are making a difference. Probably 
an important difference.                                                                                          
Feedback as 8 months •Still making 
slow progress… generally a bit more 
awake, he said quite a few interesting 
things over the course of a couple of 
hours •He now asks his son, ‘What are 
you going to do about my dementia!?’                                                                         
GP – ‘Previously this chap could spend 
days in a row asleep.’ 
2 F 65 •Previously meditated, 
now unable to think 
clearly or remember 
•Multiple amalgams  
•High carb diet with severe ‘carb 
addiction’  
•Weaned slowly off opiates 
then pregabalin 
•Supplemented with 
•Able to meditate and think again – 
cognitive dysfunction lifted as drugs 
stopped (Pregabalin - main culprit) 







•Severely low mood, 
feels she is going to die 
soon, hopelessness. 
 
Multiple comorbidities:            




dropping. Possible case 
of postural orthostatic 
tachycardia and 
hypotension (POTS).                 
•Severely obese (BMI 
40)  
•Worsening control of 
Type II diabetes, on 
Metformin and insulin 
•Arthritis  
•4 incidents of cancer 
•Hypertension  
•Fatty liver disease 
•Increased intestinal permeability 
and poor protein digestion  
•B1 and B3 deficiency  
•Severe intracellular folate 
deficiency  
•High homocysteine  
•Vitamin D deficiency  
•Hashimoto’s Hypothyroidism, TSH 
(3.29), TPO antibodies (44)  
•Multiple toxic insults (mercury 
exposure; chemo-therapy & 
radiotherapy twice) combined with 
poor methionine cycle functioning 
and nutritional deficits (PPIs and 
Metformin cause low B12), lead to 
poor metabolism of medications.  
•Probable longstanding ‘subclinical 
hypothyroidism’ may well have 
contributed to weight gain, 
metabolic syndrome and diabetes. 
•Opiates and Pregabalin added 
resulting in mitochondrial 
dysfunction with fatigue, cognitive 
dysfunction and inability to regulate 
autonomic nervous system 
methylated B complex, 
vitamin D, Mineral complex 
with extra magnesium. •B12 
injections (once B12 well 
replaced, started with 
titrated methylfolate up to 
800mcg) •Switched to low 
carb, modified Medi diet 
(gluten free) •Regular blood 
sugar monitoring and insulin 
self-adjustment under 
guidance •Probiotic •Worked 
with GP to come off insulin as 
this was causing weight gain 
and carb cravings to worsen. 
•Likely to remain at risk of 
recurring cognitive 
impairment without 
continued attention to 
reducing metabolic 
syndrome and nutritional 
support for methylation. 
•Whether heavy metals 
detoxification strategies 
would reduce dementia risk 
at this stage is not known. 
•Lost 1.5 stone in weight, down to 10 
units insulin from 40 units  
•Off all painkillers except Ibuprofen 
•Only able to tolerate 2-3 weeks 
between B12 injections – any longer 
and worsening fatigue and memory 
problems start to come back.  
•Mood much improved, starting to 
feel hopeful for the future again. 
•Over last 18 mos continued to 
improve, energy and cognitive 
function now normal for her again 
•Meditates twice a day and able to 
attend weekend retreats and 
philosophy classes  
•Does Sudoku every day, back to 
reading novels again  
•Now looks after grandchildren 2 
afternoons per week and occasional 
weekends.  
•Off insulin completely for 12 months 
3 F 76 •Progressive cognitive 
decline             
•Features of 
Parkinson’s Disease 
•Tentative diagnosis of 
•MSQ (Medical Symptom 
Questionnaire) score was 69, mainly 
symptomatic in Mind, Emotions, 
Energy and Musculoskeletal 
domains   
•Stepwise introduction of a 
therapeutic food plan, 
mitochondrial and strategic 
nutritional support and 
lifestyle measures  
•Prior to receiving results, she was 
seeming a little brighter on the 
program  
•Progress was being made. Her mood 
was improved   
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fatigue, insomnia, night 
waking, nightmares and 
distorted sense of 
smell. •Paranoia, 
fearfulness, panic 
attacks and seizure 
activity •Needed 
assistance with ADLs 
and could not easily 




•MOCA score August 
2017 14/30 with 
visuospatial, naming, 
language, attention and 




•Oral health suboptimal, many 
missing teeth, multiple amalgam 
restorations and considerable 
periodontitis    
•In AF clinically at a controlled rate 
of 72 bpm       
•Blood pressure 137/76 (R arm), 
127/76 (L arm)   
•Colonic dysbiosis, evidence of 
enterocyte stress & inflammation  
•Low levels of beneficial bacteria   
•Nutrient deficiency - profoundly 
deficient in selenium, Vitamin D 
insufficiency, suboptimal Vit B5 & 
B6, Vit C   
•Mitochondrial dysfunction on 
organic acid analysis particularly 
affecting amino acid metabolism 
•Neurotoxic markers (quinolinic 
acid)  
•Total body water was significantly 
reduced           
Medications: 12 Rx including statins, 
antidepressant, ACE inhibitor, blood 
pressure medication and Parkinson’s 
medication   
•Significant chemotoxic load 
including glyphosate, 2HIB, PGO, 
HEMA & NADB – petrochemical, 
agrochemical, styrene and rubber 
derivatives which are neurotoxic or 
•Nutrition plan includes 
Paleo reset diet, fresh 
produce, good fats, vitamins 
& other supplements, 
hydration and fasting 12 
hours a day  
•Lifestyle measures include: 
Stress reduction, Exercise, 
Oral hygiene, Regular 
elimination, Sleep hygiene, 
Breathing exercises  
•A letter was written to her 
GP with all of these details 
and a request to stop her 
statin to remove this as a 
cause of mitochondrial 
dysfunction. The GP stopped 
it for a month. 
• Her family interactions were 
markedly improving, including going 
out for walks, being able to look after 
her grandchildren one afternoon with 
her husband   
•She was doing more in the house, 
helping with chores and her daughter, 
who was visiting from xxxx, saw a 
dramatic difference in her ability to 
interact and get out and about  
•MOCA score was 20/30 having 
increased from 14/30 in 4 weeks   
•At 14 weeks significant resolution of 
cognitive, emotional and 
musculoskeletal complaints - MOCA 
score was 24/30   
•Improvement had occurred in the 
areas of visuospatial ability, memory, 
delayed recall, attention and 
orientation   
•This lady managed to travel to her 
daughter’s home after her case review 
appointment - daughter reported a 
very significant improvement in her 
overall health and cognition   
•Tragically, this lady fell and died the 
following year. 




events •Seizure activity 
•Depression & anxiety 
•Urinary leakage, 
constipation, 
incontinence                                         
•Moderate dyspnoea 
•Varicose veins 
increase the risk of CV disease and 
cancer. Notably, this lady had looked 
after her family on a farm and whilst 
not working in direct contact with 
chemicals / machinery, she had 
handled and washed her husband’s 
work clothes over the years. 
4  M 
79 
•Memory issues for 4 
years  
•Formal diagnosis of 
AD 2 years ago; on 
donepezil  
•Living in a 
Mediterranean country                 
•Very active - had been 




•Extremely low folate, Vit B9 (1.4)  
•Elevated homocysteine (19.1) 
•Vit B12 (410) within ‘normal’ limits 
but prefer it to be >500 
•Vit D (37.5) within ‘normal’ limits 
but need it optimally around 100 
•No signs of insulin resistance and 
no significant inflammation 
•HbA1c (4.94), CRP, HS CRP & ESR all 
within normal range 
Hair Toxicology Test  
•Low lithium  
•Toxic levels of aluminium, arsenic 
and tin 
Diet   
•Low carbohydrate high-fat 
(LCHF) diet to allow cells to 
metabolise glucose more 
efficiently, reverse insulin 
resistance.   
•Fructose is metabolised by 
the liver; be careful not to  
inflame it, with negative 
impacts                                              
Supplements    
•Multivitamin / mineral (C0 
q10 multi)   
•R-Omega  
•K2/D3 Vegan  
•Vitamin B12 (methyl and 
adenosyl) sublingual; 
•Probiotic fos-a-dophilus 
•Methyl Factors  
•Detox support  
•Lithium oratate  
•Chia seeds - excellent 
source of potassium                             
Initial outcomes / Follow-up at 4 
months 
“After discussion with my Mother and 
my brother we can say that there is 
some signs of slight improvement in 
his memory. For example some days 
ago he remembered that his favorite 
football Team xxxx lost that 
championship this year because the 
owner entered the football field with 
a gun in his waist in order to protest 
to the referee and of course the team 
was banned!”    
•Blood markers for folate and 
homocysteine had improved. 
Feedback at 6 months - He definitely 
had more energy and patches of 
improvement in memory                                                                     
Feedback at 8 months - Physically 
better but memory fluctuates - but 
stable overall                                                                                          
Feedback at 11 Months - "I am writing 
you about my dad’s condition. As I 
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Exercise - sitting a long time 
is very harmful; high intensity 
interval training has 
particular health benefits 
over and above other 
exercise regimes. 
Stress reduction – Bhuddify 
app; diaphragmatic breathing   
Sleep – excessive; possibly 
due to low folate levels 
have already told you he was here in 
UK during January and February when 
he started his detoxification. Here he 
had the chance to have sauna 
something that unfortunately can’t do 
back home. My mother and my 
brother that are watching his behavior 
both say that his cognitive status 
seems to be steady or even slightly 
better than before he started the 
detoxification." 
5  F 71 •AD diagnosis 2017 on 
the basis of memory 
symptoms and CT 
findings  
•She had no insight 
into her symptoms 
•Gradual decline over 
four years since 
retirement (technical 
author) – decreased 
energy, short-term 
memory and cognitive 
processing with more 
recent confusion                        
& disorientation  
•MoCA score was 
14/30  
•Examination findings 
in keeping with 
hypothyroidism; 
•Hypothyroidism from 1995; on 
thyroxine •Hypertension from 2001, 
on ACEi; beta-blocker and diuretic 
added in 2014 (shortly before the 
start of cognitive decline) •Extensive 
dental work with mercury amalgams 
in situ •Ex-smoker, significant past 
exposure to pesticides and 
chemicals •Low vit D and folate 
•Suppressed TSH with very high T4 
but low T3 •Raised homocysteine 
•Early insulin resistance - from high 
carbohydrate (CHO) diet 
(contributes to inflammation) 
•Requirement for digestive support 
•Low levels of Helicobacter pylori (H. 
pylori) without virulence factors 
•Low levels of beneficial bacteria, 
some opportunistic bacterial 
overgrowth (would impact ability to 
Diet  
•Remove gluten, dairy & 
processed foods  •Reduce 
alcohol & caffeine intake •2 
litres clear fluid/day •Balance 
blood sugar with healthy fats, 
protein & slow-release carbs 
at each meal •Organic 
produce •Water filter  
•Remove non-stick cookware 
•Sleep hygiene advice  
•Daily walk 30-60 mins 
before noon (when UV 
exposure supports circadian 
rhythm) •Brain HQ program, 
daily piano playing, daily 
relaxation listening to music, 
social interaction at least 2x 
week •Thyroid medications 
changed to NDT  
Initial follow-up at 3 months  
•MoCA score improved by 3 points to 
17/30 and patient was noticeably 
more engaged with conversation 
although short-term memory 
remained poor  
•Thyroid now functioning normal 
clinically and biochemically 
•Remained hypertensive and 
bradycardic  
•ECG showed sinus bradycardia 
•Agreed with GP to reduce beta-
blocker dose by half  
Further progress  
•Further cognitive improvement and 
engagement since reducing the beta-
blocker dose  
•Interestingly, there was a decrease in 
blood pressure  
•Stopped the beta blocker completely 







disease and vascular 
dementia but lived to 
96.                   
 
extract nutrients from food) 
•Adrenal testing revealed adequate 
production but rapid metabolism of 
cortisol •Low melatonin and likely 
low levels of all neurotransmitters 
(probably from low protein intake, 
low stomach acid & low digestive 
enzymes) •High MTBE levels (high 
toxic load) •Low glycine and 
glutathione (would impair detox 
pathways) •Low selenium and zinc 
(would impact thyroid function) 
•Lack of trophic factors was the 
main issue, indicates this is likely 
Type II AD (atrophic) according to 
Bredesen classification [97] 
•Fibroids and ovarian cysts. •Toxic 
load (mercury, pesticides, lab 
chemicals, smoking, ETOH) with 
likely poor detox pathways is also a 
contributor.                      
Initial supplements   





threonate (crosses blood 
brain barrier effectively), 
digestive enzymes and apple 
cider vinegar before each 
meal, probiotics, MCT oil, 
NAC with antioxidants, D3 
plus K2, ashwagandha 
(adaptogen that supports 
adrenals), glycine 
(glutathione precursor), EPO.  
Follow-up at 3 months 
•Supplements continued 
with the addition of 
magnesium glycinate before 
bed  
•Advised to further reduce 
(preferably stop) ETOH.  
•Patient has now read The End of 
Alzheimer's by Dr Dale Bredesen [97] 
as well as her initial clinical reports, is 
able to make insightful comments and 
suggestions  
•This is a vast improvement from our 
initial meeting  
•The latest report from her husband is 
that it seems that “the lights have 
been turned back on!” This is less than 
5 months after starting the 
interventions  
•Patient has been suffering from Type 
II or Atrophic AD due to under-treated 
hypothyroidism, decreased cerebral 
perfusion due to too much beta 
blocker medication, and lack of 
several key nutrients  
•More work to do regarding toxic load 
•Look at genetics of methylation and 







•First symptoms of 
memory loss 3 yrs prior  
•Diagnosed with AD 2 
yrs prior  
•Taking memantine  
•No significant 
previous history and no 
social or environmental 
Serum levels 
•Very low vitamin D (12.1) 
•Raised Interleukin 6 (marker of 
inflammation) 4.7 
•Some degree of insulin resistance 
but not in formal prediabetes range  
•B12, HbA1c and Folate B9 did not 
show any identifiable features but 
Diet •Low carbohydrate high-
fat (LCHF) diet to reverse 
insulin resistance, allow cells 
to metabolise glucose more 
efficiently. 
Fasting •Not eating after 
7pm and delaying breakfast 
allows the body to reset its 
•Physically stronger, more energy, 
brighter in herself but slight decline in 
memory.  
•At this stage neurotrophic 
supplements and lithium 
supplementation added.  
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history of note. already taking supplements.  
•Hair testing indicated high-ish 
levels of aluminium, arsenic, 
mercury and lead  
•Hair testing indicated low levels of 
lithium 
fuel metabolism and lower 
insulin resistance.                  
Exercise - Prolonged sitting is 
very harmful.                     
•High intensity interval 
training has particular health 
benefits beyond other 
exercise regimes.                                   
Stress reduction       
•Bhuddify app, 
diaphragmatic breathing.             
Supplements 
Multivitamin/mineral (C0 q10 
multi); R-Omega; Phyte 
Inflam; K2/D3 Vegan; Vitamin 
B12 (methyl and adenosyl) 
sublingual; Organic Vitamin B 
Complex; Probiotic fos-a-
dophilus; Magnesium 
threonate                                                                                                       
Detox Liposomal 
Glutathione; Detox Support; 
Toxaprevent Pure 
Abbreviations – ACEi (acetylcholinesterase inhibitors); AD (Alzheimer’s Disease); AF (Atrial fibrillation); BMI (Body Mass Index); Brain HQ (online brain fitness from Posit 
Science); CHO (High carbohydrate diet); ECG (Electrocardiogram); EPO (Erythropoietin); ETOH (Ethanol); MoCA (Montreal Cognitive Assessment); MSQ (Medical Symptom 
Questionnaire) [MSQ lists 71 possible symptoms in 15 domains. Scores from 0–284; lower score = less symptoms]; MTBE (toxin, Methyl tert-butyl ether); 2HIB (toxin, 2-
Hydroxyisobutyric Acid);   HEMA (toxin, monomer used to make various polymers); & NADB (rubber toxin); TSH (cholera toxin); T3 (thyroid hormone triiodothyronine); T4 
(thyroid hormone thyroxine); NAC (N-acetylcysteine); NDT (Natural Dessicated Thyroid);   CRP (C-reactive protein); HS (High-sensitivity); ESR (Erythrocyte sedimentation 
rate);  CRP & ESR (markers of inflammation). 
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4.4 Key Points, Insights and Findings 
The 11 key points below summarise some insights gained, and tentative findings from these six 
case reports. By looking at cognitive impairment as one small piece of a larger puzzle these key 
points further illustrate the unique and potentially beneficial aspects of this treatment approach.  
1. Not just a memory problem – Dementia is not a solitary problem of memory but is often one 
of a mixture of conditions and part of wider health issues. Lifestyle appropriate for addressing 
dementia has positive side-effects on other conditions.  
2. Never too late to start – [CS1 – Case Study 1] A male in his mid 90s is very weak and frail, 
cannot walk and requires 24-hour assistance with all ADLs from a son with whom he lives. After an 
in-depth investigation by the FM practitioner, the son initiated dietary changes, further 
supplements and an exercise regime. “He has begun to help me a bit more than before when I ask 
him to move an arm or lift a leg or bend forward.  If his brain is slowly waking up it must be 
difficult for him - to more fully realise his circumstances. He improves most after a fasting episode.”  
3. Success requires family support – *CS1+ “Bananas brought on a relapse a month ago when I 
gave him banana every day for about a week - it ended with him not recognising me.” “Relapses 
occur when I get tired of trying to help him or when I try too hard.” “Exercise is very important. As 
well as exercising his legs with a Reck MOTOmed I have now got him a Motovator Medidrive - 
which bicycles his hands and arms.  He has been using that for a week and the difference is 
noticeable.” “I have been trying to take him swimming as often as I can, but the last time was two 
weeks ago. The sheer effort of it puts me off - but it is very good for him.  Best would be every 
day...!” “I am now including five of Bredesen’s [97] Indian herb supplements, as well as the ones 
you recommended.  I think they are making a difference. Probably an important difference.” 
4. Nutrient deficiencies – Each case had abnormal nutrient levels with implications for brain 
health. “Profoundly deficient in selenium (red cell analysis), Vitamin D insufficiency 39ng/ml 
(optimum 50-80ng/ml), suboptimal vitamins B5 & B6, Vitamin C.”*CS3+  “PPIs (proton pump 
inhibitors) & Metformin cause low B12.”*CS2+ There is a role therefore, for B12 injections to be 
started right away with all memory problems. Patients can easily be taught to self-inject. 
Nutritional support is also needed for methylation, or run the “risk of recurring cognitive 
impairment” *CS2+. “Curcumin is anti-inflammatory. Magnesium ascorbate provides antioxidant 
support, and Magnesium threonate crosses the blood brain barrier effectively.” *CS5+. 
5. Prescription medications – “Opiates and Pregabalin may result in mitochondrial dysfunction 
with fatigue, cognitive dysfunction and inability to regulate autonomic nervous system.”*CS2+ 
Pregabalin side effects include sleepiness, confusion and memory impairment. Statins cause 
mitochondrial dysfunction. PPIs (proton pump inhibitors) reduce acid formation in the stomach to 
prevent ulcers, but long term PPI use has been linked to dementia and vitamin B12 deficiency. 
Beta blockers (beta-adrenergic blocking agents) block adrenaline from binding to beta receptors 
on nerves; act to reduce heart rate/blood pressure by dilating blood vessels) (see CS5 about 
dropping these). 
6. Mis/undiagnosed/untreated/under-treated thyroid function – “Probable longstanding 
‘subclinical hypothyroidism’ may well have contributed to weight gain, metabolic syndrome and 
diabetes.”*CS2+ “Type II or Atrophic AD is due to under-treated hypothyroidism, decreased 
cerebral perfusion due to too much beta blocker medication, and lack of several key 
nutrients.”*CS5+  “Low selenium and zinc would impact thyroid function.”*CS4+. 
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7. Toxicity, heavy metals, pesticides, infection – Mercury exposure from dental amalgams was 
evident in half of the cases, whereas chemotherapy [CS4] or other chemotoxic loads (pesticides, 
lab chemicals, smoking, ETOH, glyphosate, petrochemicals, agrochemicals) or heavy metals 
(mercury, aluminium, tin, arsenic)  were evident in all cases. “Oral health was suboptimal with 
many missing teeth, multiple amalgam restorations and considerable periodontitis and hard and 
soft plaque.” *CS4+; “Low glycine and glutathione would impair detox pathways.”*CS5+ 
8. Connection to diabetes – “Worked with GP to come off insulin as this was causing weight 
gain and carb cravings to worsen.”*CS2+ “Early insulin resistance - from high carbohydrate (CHO) 
diet contributes to inflammation.”*CS5+. 
9. Gut-Brain connection – stomach acid and beneficial bacteria – Low stomach acid and low 
digestive enzymes [CS5]; There is a requirement for digestive support for low levels of beneficial 
bacteria, as some “(o)pportunistic bacterial overgrowth would impact ability to extract nutrients 
from food.”*CS5+. 
10. Dehydration and fasting – *CS1+ “(my father) improves most after a fasting episode.” “Total 
body water was significantly reduced at 32.8 l (predicted optimal 36-43 l)”*CS5+. 
11. Metabolic syndrome presents continued risk for cognitive impairment – “Likely to remain at 
risk of recurring cognitive impairment without continued attention to reducing metabolic 
syndrome and nutritional support for methylation.”*CS2+. 
5. Discussion 
These observations provide further support to the growing body of case reports describing 
reversal of cognitive decline in patients with early Alzheimer’s or other dementias. To our 
knowledge, this is the first paper reporting practitioner case reports documenting improvements 
in symptomatology of memory decline in patients from the UK, Greece and New Zealand. Four 
patients had their initial presentations and follow-up improvements verified by MoCA and/or a 
formal diagnosis, and two patients had symptom improvements verified through self-report and 
proxy-report.  
Improvements were shown through biomarkers, such as normalisation of serum levels, folate 
and homocysteine, thyroid function, blood sugar levels, as well as weight loss, decreased blood 
pressure and reduction in medications (beta-blockers, statins, insulin, metformin, pregabalin and 
painkillers). 
Improvements were also reported in: cognitive function, memory, visuospatial ability, delayed 
recall, attention, orientation, overall health, physical strength, communication, clarity, mood, 
emotions, feeling hopeful for the future, lifting of brain fog, energy levels, a bit more awake, 
reading, ability to meditate, doing Sudoku, going out, socialising, looking after grandchildren, 
going for walks, helping with chores, visiting family, interacting, engagement in conversation and 
making insightful comments and suggestions.  
A small but growing body of evidence illustrates through N-of-1 case studies or case reports the 
process, practice and progress of patients presenting with cognitive decline. This paper has 
contributed a few more. Limitations are many. The particular analyses and interventions are not 
uniform across the practitioners, nor were consistent measures taken at baseline and beyond. 
There was no uniformity of diagnoses, except that a clear presence of cognitive decline was 
reported, measured or diagnosed. Further limitations of case reports include sample size (n=1) 
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and lack of control or randomisation. In the case of any treatment for dementia, ‘usual care’ spells 
ultimate decline [98, 99] acting as a control whereby any stability in symptoms or delay in decline 
can be interpreted as improvement [100, 101]. Furthermore, as this is a multimodal intervention 
involving a wide range of treatments, it is impossible to correlate improvement with any one 
mode. As this is not mono-therapy drug research, there is no need or intention to isolate any 
particular intervention. If a mono-therapy could treat dementia it would be marketed already. The 
multi-domain nature of dementia and the multimodal treatments of IM practitioners advocate for 
a medical paradigm shift towards an ecological model where health is determined by a complex 
interaction of factors at different levels, including the realms of energy [102] and intent [103].  
There is also an epistemological argument to be made whereby empiricism concerns only 
knowledge gained through sense experience. Most energy medicine operates beyond the narrow 
bandwidths of human sensing and is often dismissed as scientifically impossible simply because 
modern empirical science, and therefore conventional medicine fails to understand it. This is 
blaming a fish for not being able to ride a bicycle. But this is slowly changing as technology evolves 
to record, measure and verify the body’s energy field or ‘biofield’ [104]. The biofield is a 
‘multilevel organizational concept in which information flows within and between the various 
levels of the organism’ [103]. Biofield therapy [104] is non-invasive and involves practitioner 
interactions with the client’s biofields, interacting fields of energy and information both within and 
around living systems [105-107], capturing an “aspect of healing beyond limited implication of 
medicine as a treatment for illness,” [103] but also in clinical studies reducing pain, negative 
behavioural symptoms in dementia and anxiety in hospitalised populations [108, 109]. The 
possibilities are staggering - “The ability to understand and control shape in its most general form 
offers the opportunity to address a wide range of biomedical problems and restore complex 
structures damaged by injury, cancer, disease or age.” [105.]  
With these case reports, regardless of which mode was most efficacious, an outcome of 
improvement for the patient is our optimal concern. These findings lend further supportive 
evidence to silence the dominant narrative that dementia is incurable and irreversible. 
5.1 Future Directions 
We advocate for personalised medicine within the UK National Health Service (NHS) for 
persons living with memory problems and dementia [110]. Approaching a chronic multifactorial 
condition in this manner is relatively new to the UK, but attracting attention elsewhere [111]. A 
‘root cause’ FM approach to cognitive decline or dementia is not available through the NHS, nor is 
it clear as to the extent of global availability. Practitioners are being trained around the world and 
starting private practice, but we are unaware of any present government health service provision. 
The availability of FM practitioners motivates resourceful individuals to implement multiple 
difficult lifestyle changes, subsequently contributing data to case reports, as above. 
There is a pressing need for interventions that can modify the disease process and affect 
measurable improvement in cognition and associated benefits to quality of life for patients and 
caregivers. We therefore aim to draw upon the latest evidence, learn from existing projects 
worldwide and develop the next phase of the work: a logistically practical, affordable, holistic, 
enhanced intervention alongside the existing NHS memory service pathway. However, lifestyle 
change can be difficult for older people as it may involve changing or relinquishing cherished 
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habits and routines, as well as challenging long-held perceptions and beliefs around dementia, its 
causes and the possibility of change through treatments. Crucially, in designing the intervention 
protocol, we aim to assist participants and their caregivers to overcome the major physical, 
emotional, environmental and psychological hurdles associated with behaviour change [112]. To 
facilitate this goal, substantial engagement with people with early-stage dementia, caregivers and 
practitioners is ongoing. 
6. Conclusions 
Existing evidence and workable protocols emerging from personalised medicine regarding the 
arrest and reversal of cognitive decline in symptomatic individuals opens a new window for 
research and care practice. The suitability of this approach to dementia is evident given the 
multiple causative factors identified to date. Personalised multimodal medicine provides a potent 
cocktail targeting several individual causative factors through in-depth investigation and root 
cause analysis, resulting in the disruption of neurodegenerative mechanisms. Although this 
systems approach seems novel and ground-breaking, it merely reinforces ancient mind-body-spirit 
traditions of treating the person, not the disease, by way of energy that contributes information 
for a person’s mental, emotional, physical, and spiritual wellbeing [107]. Such practices continue 
to sustain lives around the world today.   
The window of opportunity for intervention is when subjective impairment or early-stage 
dementia renders the person both aware of their circumstance and cognitively able to address it. 
A proposed collaborative project between Lancaster University and the NHS in the UK will offer an 
enhanced level of intervention alongside the existing NHS memory assessment service pathway. 
Support for lifestyle change will be perhaps the most critical factor in success for these patients - 
helping them to overcome the major physical, emotional, environmental and psychological 
hurdles they will face. 
Beyond the paradigm of ‘living well with’ dementia, existing treatment protocols are facilitating 
a future whereby people with dementia and their loved ones can ‘live well beyond’ diagnosis. 
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